Gilmore O'Neill compensation by year
Sarepta Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
| Salary | $310,962 | $563,962 | $583,277 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $1,154,760 | $0 | $766,949 |
| Option awards | $4,768,050 | $4,234,786 | $2,131,159 |
| Non-equity incentive | $213,354 | $354,063 | $293,164 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $2,050 | $15,300 | $15,500 |
| Total | $6,449,176 | $5,168,110 | $3,790,049 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sarepta Therapeutics, Inc. DEF 14A filed April 20, 2021, accession 0001564590-21-019631, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Sarepta Therapeutics, Inc. filed document, accession 0001564590-21-019631. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2021.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 3,750 | $337,688 | — |
| RSU | 1,675 | $150,834 | — |
| OPTION | 58,853 | — | $87.11 |
| OPTION | 12,500 | — | $96.23 |
| OPTION | 16,489 | — | $145.48 |
| OPTION | 19,433 | — | $114.47 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Sarepta Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Sarepta Therapeutics’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Louise Rodino-Klapac | Executive Vice President, Chief Scientific Officer | $7,269,509 |
| David Howton | Executive Vice President, General Counsel and Corporate Secretary | $5,703,078 |
| Ian Estepan | Executive Vice President, Chief Financial Officer | $5,177,681 |
| Gilmore O'Neill · this page | M.B. Executive Vice President, Chief Scientific Officer | $3,790,049 |
| Sandesh Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer | $3,364,021 |
| Douglas Ingram | President and Chief Executive Officer | $1,291,947 |
| Joseph Bratica | Vice President, Corporate Controller | $911,887 |
| William Ciambrone | Executive Vice President, Technical Operations | $679,938 |
The full Sarepta Therapeutics compensation record
free company briefThis page is one person within Sarepta Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Sarepta Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sarepta Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.